Core Financial Performance - The bank reported core earnings of DKK 2,321 million and a net profit of DKK 1,753 million for the first three quarters of 2025, reflecting a 21% annual return on equity [1][4] - Total core income for the first three quarters of 2025 was DKK 3,073 million, slightly higher than the same period in 2024 [4] - Earnings per share increased by 4% to DKK 71.2 for the first three quarters of 2025 [4] Expense Management - Total expenses and depreciation amounted to DKK 534 million, a decrease from DKK 761 million in the same period of 2024 [2] - The cost/income ratio improved to 25.6%, indicating effective cost management despite a 4% increase in costs [4] Credit Quality and Impairment Charges - The bank maintained strong credit quality, with impairment charges of DKK 11 million recorded in the quarter, leading to total impairment charges of DKK 35 million for the first three quarters of 2025 [4] - Impairment charges for loans showed a positive trend, with a charge of +24 million in the first three quarters of 2025 compared to +2 million in 2024 [2] Customer Growth and Loan/Deposit Trends - The bank experienced a satisfactory increase in customer numbers, with loans growing at a rate of 7% per annum and deposits at 9% per annum [4]

Core Points - Sampo plc has conducted a share buyback on 21 October 2025, acquiring a total of 351,896 A shares at an average price of EUR 9.66 per share [1][2] - The share buyback program, announced on 6 August 2025, has a maximum limit of EUR 200 million and is in compliance with the Market Abuse Regulation [1] - Following the transactions, Sampo plc now holds a total of 18,131,091 A shares, which represents 0.67% of the total shares outstanding [2] Summary by Sections Share Buyback Details - On 21 October 2025, Sampo plc acquired 351,896 A shares across various markets, with the daily weighted average price being EUR 9.66 [1] - The buyback was executed on multiple exchanges, including AQEU, CEUX, TQEX, and XHEL [1] Program Announcement - The share buyback program was initiated on 7 August 2025, following authorization from Sampo's Annual General Meeting held on 23 April 2025 [1] - The program aims to utilize up to EUR 200 million for the buyback of shares [1] Ownership Post-Transaction - After the buyback transactions, Sampo plc's total ownership of A shares stands at 18,131,091, equating to 0.67% of the total shares [2]

Core Insights - Novartis announced that Cosentyx® (secukinumab) achieved significant results in the Phase III REPLENISH trial for treating polymyalgia rheumatica (PMR), meeting both primary and secondary endpoints [1][7] - The trial demonstrated that Cosentyx provided sustained remission compared to placebo at Week 52, indicating its potential as a novel treatment option for PMR [1][7] Company Overview - Novartis is an innovative medicines company focused on improving and extending patients' lives through advanced therapies, reaching nearly 300 million people globally [9] Product Information - Cosentyx is a fully human biologic that inhibits interleukin-17A, a key cytokine in various immune-mediated inflammatory diseases, and is already approved for multiple conditions including psoriatic arthritis and ankylosing spondylitis [4] - Since its launch in 2015, Cosentyx has treated over 1.8 million patients worldwide and is approved in more than 100 countries [4] Clinical Trial Details - The REPLENISH trial was a global Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted in 27 countries, assessing the efficacy and safety of Cosentyx in PMR patients [3] - The primary endpoint was to determine if secukinumab 300mg plus a steroid taper was superior to placebo plus a steroid taper in achieving sustained remission at Week 52 [3] Disease Context - Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 and older, characterized by significant pain and stiffness, which can severely impact quality of life [5] - Long-term steroid use, the standard treatment, poses risks such as osteoporosis and diabetes, highlighting the need for effective alternatives like Cosentyx [5]

EfTEN Capital AS, as the management company of the EfTEN United Property Fund (stock market ticker EFCUPFFT, ISIN code EE3500001609) decided to make a cash distribution of 16,900 euro cents per unit, totalling 419 772 euros. The distribution constitutes approximately 2% of the fund’s latest closing price. This is the second distribution of the EfTEN United Property Fund in 2025 and together with the distribution in May, the fund has distributed over 9% of the market cap in 2025. Since the listing of EfTEN ...

Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0%2 at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior guidance greater than 32. ...

Merger of equals to create new global critical minerals champion and unlock substantial valueVANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. "The merger of equals between Teck and Anglo American announced this quarter is a unique opportunity to create a global leader in critical minerals and a top five copper producer," said Jonathan Price, President and CEO. "The c ...

Borregaard’s operating revenues were NOK 1,799 million (NOK 1,949 million)2 in the 3rd quarter of 2025. EBITDA1 was NOK 440 million (NOK 524 million). The result in BioSolutions increased while BioMaterials and Fine Chemicals had lower results compared with the 3rd quarter of 2024. The reduced EBITDA1 was due to lower bioethanol prices and the temporary disruption in cellulose production at the Sarpsborg site. The negative impact from this disruption amounts to approximately NOK 40 million. The improvement ...

By the end of the Q3 2025, Coop Pank had 222,000 customers, increased by 4,000 customers in the quarter (+2%) and by 20,000 in the year (+10%). The bank had 105,400 active customers, increased by 1,800 (+2%) in the quarter and by 10,000 (+10%) in the year. In Q3 2025, volume of deposits in Coop Pank increased by 105 million euros (+6%), reaching total of 1.91 billion euros. Deposits from private customers increased by 9 million euros: demand deposits remained at the same level compared to the previous quar ...

VIENNA, Austria – October 22, 2025 – Today, BAWAG Group released its results for the third quarter 2025. The operating performance of our business remained strong with a net profit of €219 million, earnings per share of €2.77, and a RoTCE of 27.8%. Pre-provision profits were at €354 million and the cost-income ratio at 36.1%. This resulted in a net profit of €630 million, €7.98 earnings per share and a RoTCE of 26.9% for the first nine months 2025. The CET1 ratio was at 14.1% after the deduction of the divi ...

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing purchase price of 350 ...